Compare AIRS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | NYXH |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.4M | 137.5M |
| IPO Year | 2021 | 2021 |
| Metric | AIRS | NYXH |
|---|---|---|
| Price | $1.26 | $1.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $4.50 | $4.20 |
| AVG Volume (30 Days) | ★ 822.7K | 148.1K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $151,818,000.00 | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | $2.65 | $93.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $1.19 |
| 52 Week High | $12.00 | $6.00 |
| Indicator | AIRS | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 22.98 | 31.61 |
| Support Level | N/A | N/A |
| Resistance Level | $3.31 | $1.69 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.65 | 2.50 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.